Tofflon

Tofflon Science and Technology Group ranks among China’s largest pharmaceutical equipment manufacturers, with over three decades of experience providing process services, core equipment, and engineering solutions to pharmaceutical companies worldwide. The company operates through its medical equipment subsidiary, Shanghai Dongfulong Medical Equipment Co., Ltd., which develops the Kino series of VHP (Vaporized Hydrogen Peroxide) disinfection robots for healthcare and pharmaceutical applications.

Company Overview

Established in 1993 and listed on the Shenzhen Stock Exchange ChiNext board in February 2011, Tofflon has grown from a domestic pharmaceutical equipment supplier into a full-service provider serving clients across more than 50 countries. The company’s development philosophy centers on “systematization, internationalization, and digitalization,” enabling it to deliver end-to-end pharmaceutical manufacturing solutions.

Tofflon operates through four core business segments: Bioprocessing, Formulation Equipment, Pharmaceutical Engineering, and Food Engineering. With 26 domestic subsidiaries, 13 overseas holding subsidiaries, 8 manufacturing bases globally, and 3 R&D centers, the company maintains a substantial international presence in the pharmaceutical equipment sector.

Product Line

Kino VHP Disinfection Robot

Developed by Shanghai Dongfulong Medical Equipment Co., Ltd., the Kino represents China’s first intelligent VHP disinfection system. The robot uses proprietary flash evaporation technology to rapidly distribute vaporized hydrogen peroxide throughout enclosed spaces, achieving 6-log microbial reduction. The system targets bacteria, spores, fungi, mold, and viruses with broad-spectrum efficacy.

Pharmaceutical Equipment Systems

Beyond disinfection robots, Tofflon provides pharmaceutical manufacturing equipment including freeze-drying systems, bioreactors, filling lines, isolator systems, and packaging solutions. The company’s equipment portfolio serves biologics manufacturing, cell and gene therapy production, and traditional pharmaceutical formulation processes.

Cell Processing Systems

Through its medical equipment division, Tofflon offers GMP-compliant cell drug preparation platforms and automated liquid nitrogen storage management systems, supporting the growing cell therapy manufacturing sector.

Innovation Focus

Tofflon’s VHP disinfection technology employs flash evaporation to generate high-temperature hydrogen peroxide vapor that reaches saturation levels within enclosed spaces. When the saturated vapor contacts cooler surfaces, it forms micrometer-scale condensation layers that release highly oxidative free radicals upon contact with metal ions or light. These free radicals attack cell membranes and DNA, inactivating microorganisms within extremely short timeframes.

The company holds multiple patents related to its disinfection technology and maintains dedicated R&D centers focused on advancing pharmaceutical equipment automation and intelligence.

Industry Position

With over 10,000 pharmaceutical equipment units deployed globally, Tofflon serves approximately 3,000 pharmaceutical companies across more than 50 countries. The company’s disinfection robots gained significant visibility during the COVID-19 pandemic when donated units were deployed to Wuhan Jinyintan Hospital, Wuhan Union Hospital, Wuhan Dongxihu People’s Hospital, and Wuhan Zhongnan Hospital.

The Kino disinfection robot has also found application in public transit systems, including deployment for the Hong Kong MTR disinfection program during the pandemic response period.

Development History

• 1993: Company founded in Shanghai
• 2011: Listed on Shenzhen Stock Exchange ChiNext (300171.SZ)
• 2020: Donated VHP disinfection robots to Wuhan hospitals during COVID-19 outbreak
• 2023: Achieved over 10,000 equipment installations globally

Key Information

How widely deployed is Tofflon’s technology?

Tofflon is expanding its commercial footprint with installations at leading medical centers.

Where is Tofflon listed?

The company trades on the Shenzhen Stock Exchange.

What distinguishes Tofflon’s engineering approach?

Tofflon focuses on purpose-built engineering, clinical validation, and addressing unmet needs in surgical robotics.

How much capital has Tofflon raised?

Investment in Tofflon has reached $8M from venture and corporate backers.